Home » Topics » BioWorld Science

BioWorld Science
RSS

Antibe places its AME study of otenaproxesul on required pause

Aug. 4, 2021

LSD1 as potential therapeutic target in heart failure

Aug. 4, 2021

Cyclin C controls responses to PARP inhibitor treatment in BRCA2-deficient cells

Aug. 4, 2021

Luye Pharma files IND in U.S. to study next-generation VMAT2 inhibitor LY-03015

Aug. 3, 2021

FDA authorizes IND for phase I testing of Sorrento's CD38 DAR-T cell therapy candidate

Aug. 3, 2021

ACD-856 shows preclinical effects on cognition, enters phase I study

Aug. 3, 2021

Annovis reports interim phase II data on Posiphen in Alzheimer's and Parkinson's disease

Aug. 3, 2021

Dosing underway in phase I/II study of KRAS G12C inhibitor JAB-21822

Aug. 3, 2021

CTA approved in Vietnam for phase I/II/III study of SARS-CoV-2 vaccine ARCT-154

Aug. 3, 2021

Phase I data with ANG-3070 pave way for phase II study in primary proteinuric kidney diseases

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...